Equities

Novartis AG

0QLR:LSE

Novartis AG

  • Price (CHF)120.36
  • Today's Change0.82 / 0.69%
  • Shares traded1.67m
  • 1 Year change21.63%
  • Beta0.7783
Data delayed at least 20 minutes, as of Feb 06 2026 18:28 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in CHF (TTM)43.70bn
  • Net income in CHF10.85bn
  • Incorporated1996
  • Employees75.88k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QLR:LSE since
announced		Transaction
value
Avidity Biosciences IncAnnounced26 Oct 202526 Oct 2025Announced15.64%9.99bn
Tourmaline Bio IncDeal completed09 Sep 202509 Sep 2025Deal completed17.63%1.37bn
Regulus Therapeutics IncDeal completed30 Apr 202530 Apr 2025Deal completed27.76%1.62bn
Anthos Therapeutics IncDeal completed11 Feb 202511 Feb 2025Deal completed24.16%3.08bn
Data delayed at least 20 minutes, as of Feb 06 2026 18:28 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.